A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Phase 1 Study of the Safety and Tolerability of the Intravenous Administration of Thymosin Beta 4 and Its Pharmacokinetics After Single and Multiple Doses in Healthy Volunteers.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Phase 1 Study of the Safety and Tolerability of the Intravenous Administration of Thymosin Beta 4 and Its Pharmacokinetics After Single and Multiple Doses in Healthy Volunteers.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Thymosin-beta-4 (Primary)
  • Indications Myocardial infarction
  • Focus Adverse reactions
  • Sponsors RegeneRx Biopharmaceuticals
  • Most Recent Events

    • 13 Apr 2017 Status changed from completed to withdrawn prior to enrolment.
    • 23 Mar 2015 Status changed from suspended to completed as reported by ClincialTrials.gov
    • 25 Apr 2014 Status changed from completed to suspended as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top